CD44 and glioblastoma: In addition, when combined with standard GBM drugs (temozolomide and carmustine), CD44 depletion induced tumour cell apoptosis through the activation of caspase-3 and ROS-induced cytotoxic stress, culminating in a synergistic inhibition of intracranial tumour progression, further prolonging the median survival time of mice.